查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1412279

学名药市场：按类型、给药途径、适应症、分布划分 - 全球预测 2024-2030

Generic Drugs Market by Type (Simple Generic, Specialty Generic), Route of Administration (Inhalable, Injectable, Oral), Indication, Distribution - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年学名药市场规模为2,991.6亿美元，预计2024年将达3,162.7亿美元，2030年将达4,474.5亿美元，复合年增长率为5.91%。

全球学名药市场

主要市场统计
基准年[2023] 2991.6亿美元
预测年份 [2024] 3162.7亿美元
预测年份 [2030] 4474.5亿美元
复合年增长率（%） 5.91%
仿製药市场-IMG1

FPNV定位矩阵

FPNV定位矩阵对于评估学名药市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出资讯的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对学名药市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵考察，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更资讯的决策并制定有效的策略，从而在市场上获得竞争优势。

该报告对以下几个方面提供了宝贵的见解：

1-市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2-市场开拓：我们深入研究利润丰厚的新兴市场并分析其在成熟细分市场的渗透率。

3- 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4-竞争力评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5- 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1-学名药市场的市场规模和预测是多少？

2-在学名药市场预测期内需要考虑投资的产品、细分市场、应用和领域有哪些？

3-学名药市场的技术趋势和法律规范是什么？

4-学名药市场主要厂商的市场占有率是多少？

5-进入学名药市场合适的型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性病的流行和对高性价比药物的需求
      • 政府对学名药的有利核准
      • 扩大网路药局学名药的可得性
    • 抑制因素
      • 病人和医生对品牌药物的偏好
    • 机会
      • 正在进行的与学名药相关的研究和开发活动
      • 专利到期延长和学名药生产策略长期合作伙伴关係
    • 任务
      • 对品质和製造差异的担忧
  • 市场区隔分析
  • 市场趋势分析
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法律规范

第六章学名药市场：按类型

  • 简单非专利
  • 专门食品非专利

第七章学名药市场：依给药途径

  • 吸入式
  • 可注射的
  • 口服

第八章学名药市场（按适应症）

  • 癌症
  • 心血管疾病
  • 中枢神经系统疾病
  • 糖尿病
  • 消化系统疾病
  • 荷尔蒙与相关疾病
  • 感染疾病
  • 呼吸系统疾病

第九章学名药市场分布

  • 医院药房
  • 网路药房
  • 零售药房

第十章美洲学名药市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区学名药市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲、中东和非洲学名药市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争形势

  • FPNV定位矩阵
  • 市场占有率分析：主要企业
  • 主要企业竞争情境分析

第14章竞争产品组合

  • 主要公司简介
    • Abbott Laboratories
    • Aspen Holdings
    • Aurobindo Pharma
    • Baxter International Inc.
    • Dr. Reddy's Laboratories Ltd.
    • Eli Lilly and Company
    • Endo International plc.
    • Fresenius SE & Co. KGaA.
    • Gilead Sciences, Inc.
    • GlaxoSmithKline PLC
    • Glenmark Pharmaceuticals Ltd.
    • Hikma Pharmaceuticals PLC.
    • Johnson & Johnson Services, Inc.
    • Lupin
    • Mylan Laboratories Limited
    • Pfizer Inc.
    • Sandoz International GmbH by Novartis Group
    • Sanofi
    • STADA Arzneimittel AG
    • Sun Pharmaceutical Industries Ltd.
    • Teva Pharmaceuticals Industries Ltd.
  • 主要产品系列

第十五章附录

  • 讨论指南
  • 关于许可证和定价
Product Code: MRR-F6513A06BEC0

[195 Pages Report] The Generic Drugs Market size was estimated at USD 299.16 billion in 2023 and expected to reach USD 316.27 billion in 2024, at a CAGR 5.91% to reach USD 447.45 billion by 2030.

Global Generic Drugs Market

KEY MARKET STATISTICS
Base Year [2023] USD 299.16 billion
Estimated Year [2024] USD 316.27 billion
Forecast Year [2030] USD 447.45 billion
CAGR (%) 5.91%
Generic Drugs Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Generic Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Generic Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Generic Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Aspen Holdings, Aurobindo Pharma, Baxter International Inc., Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Endo International plc., Fresenius SE & Co. KGaA., Gilead Sciences, Inc., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Hikma Pharmaceuticals PLC., Johnson & Johnson Services, Inc., Lupin, Mylan Laboratories Limited, Pfizer Inc., Sandoz International GmbH by Novartis Group, Sanofi, STADA Arzneimittel AG, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceuticals Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Generic Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Simple Generic
    • Specialty Generic
  • Route of Administration
    • Inhalable
    • Injectable
    • Oral
  • Indication
    • Cancer
    • Cardiovascular Diseases
    • Central Nervous System Disorders
    • Diabetes
    • Gastrointestinal Diseases
    • Hormones & Related Diseases
    • Infectious Diseases
    • Respiratory Diseases
  • Distribution
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Generic Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Generic Drugs Market?

3. What are the technology trends and regulatory frameworks in the Generic Drugs Market?

4. What is the market share of the leading vendors in the Generic Drugs Market?

5. Which modes and strategic moves are suitable for entering the Generic Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Generic Drugs Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of chronic diseases and need for cost-effective medications
      • 5.1.1.2. Favorable government approvals for generic drugs
      • 5.1.1.3. Growing availability of generic drugs through online pharmacies
    • 5.1.2. Restraints
      • 5.1.2.1. Preference for branded drugs by patients and physicians
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing R&D activities associated with generic drugs
      • 5.1.3.2. Increasing patent expirations and strategic long-term partnerships to manufacture generic drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with quality and manufacturing variability
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Generic Drugs Market, by Type

  • 6.1. Introduction
  • 6.2. Simple Generic
  • 6.3. Specialty Generic

7. Generic Drugs Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Inhalable
  • 7.3. Injectable
  • 7.4. Oral

8. Generic Drugs Market, by Indication

  • 8.1. Introduction
  • 8.2. Cancer
  • 8.3. Cardiovascular Diseases
  • 8.4. Central Nervous System Disorders
  • 8.5. Diabetes
  • 8.6. Gastrointestinal Diseases
  • 8.7. Hormones & Related Diseases
  • 8.8. Infectious Diseases
  • 8.9. Respiratory Diseases

9. Generic Drugs Market, by Distribution

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Americas Generic Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Generic Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Generic Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
  • 13.2. Market Share Analysis, By Key Player
  • 13.3. Competitive Scenario Analysis, By Key Player

14. Competitive Portfolio

  • 14.1. Key Company Profiles
    • 14.1.1. Abbott Laboratories
    • 14.1.2. Aspen Holdings
    • 14.1.3. Aurobindo Pharma
    • 14.1.4. Baxter International Inc.
    • 14.1.5. Dr. Reddy's Laboratories Ltd.
    • 14.1.6. Eli Lilly and Company
    • 14.1.7. Endo International plc.
    • 14.1.8. Fresenius SE & Co. KGaA.
    • 14.1.9. Gilead Sciences, Inc.
    • 14.1.10. GlaxoSmithKline PLC
    • 14.1.11. Glenmark Pharmaceuticals Ltd.
    • 14.1.12. Hikma Pharmaceuticals PLC.
    • 14.1.13. Johnson & Johnson Services, Inc.
    • 14.1.14. Lupin
    • 14.1.15. Mylan Laboratories Limited
    • 14.1.16. Pfizer Inc.
    • 14.1.17. Sandoz International GmbH by Novartis Group
    • 14.1.18. Sanofi
    • 14.1.19. STADA Arzneimittel AG
    • 14.1.20. Sun Pharmaceutical Industries Ltd.
    • 14.1.21. Teva Pharmaceuticals Industries Ltd.
  • 14.2. Key Product Portfolio

15. Appendix

  • 15.1. Discussion Guide
  • 15.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. GENERIC DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. GENERIC DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GENERIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GENERIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GENERIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GENERIC DRUGS MARKET DYNAMICS
  • FIGURE 7. GENERIC DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GENERIC DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 10. GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GENERIC DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 12. GENERIC DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 14. GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES GENERIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES GENERIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. GENERIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 24. GENERIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. GENERIC DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GENERIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GENERIC DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. GENERIC DRUGS MARKET SIZE, BY SIMPLE GENERIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. GENERIC DRUGS MARKET SIZE, BY SPECIALTY GENERIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 9. GENERIC DRUGS MARKET SIZE, BY INHALABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GENERIC DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GENERIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 13. GENERIC DRUGS MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GENERIC DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GENERIC DRUGS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GENERIC DRUGS MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GENERIC DRUGS MARKET SIZE, BY GASTROINTESTINAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GENERIC DRUGS MARKET SIZE, BY HORMONES & RELATED DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GENERIC DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GENERIC DRUGS MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 22. GENERIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GENERIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GENERIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES GENERIC DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 193. GENERIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 194. GENERIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 195. GENERIC DRUGS MARKET LICENSE & PRICING